Search

The IC50 of BJ-1301, α-TOH, and sunitinib with respect to receptor tyrosine kinases

Specific actions of VEGF and BJ-1301 in NOX2 protein expression. Protein extracts from HUVECs treated with indicated concentration of BJ-1301 were loaded on SDS PAGE together with His-tagged human NOX1 (NOX1-1359H, Creative Biomart, NY, USA ), His+T7-tagged human NOX2 (LSG25251, LifeSpan Biosciences, WA, USA), and GST-tagged human NOX-4 (NOX4-1336H, Creative Biomart, NY, USA) recombinant proteins. Each isoform of NOX proteins was detected by using anti-NOX1 (ab55831, Abcam, MA, USA), anti-NOX2 (ab129068, Abcam, MA, USA), or anti-NOX4 (ab109225, Abcam, MA, USA) antibody. The membranes were reprobed to get the immunoblot of His, T7 or GST protein using anti-His (A00186100, Genscript, NJ, USA), anti-T7 (ab97964, Abcam, MA, USA), or anti-GST (ab19256, Abcam, MA, USA) antibody, respectively.

The IC50 values of BJ-1301, SU4312, and α-TOH on ROS production induced by VEGF and TPA

Primer sequences used in the PCR experiments

The Absolute mRNA expression (Ct andã…¿Ct values*) of NOX isoforms and regulatory subunits in A549 and H1299 cells

Comparison of ID50 of BJ-1301 and α-TOH in VEGF-induced angiogenesis in vivo

Background: Chaperon-mediated autophagy (CMA) is a target specific degradation pathway among autophagic processes. Although CMA plays critical roles in tumor progression in general, the role of CMA in tumor progression under hypoxia is poorly understood. We investigated the role of CMA in hypoxic tumor using a novel Hsp90-mediated modulator of CMA.Methods: We examined whether manassantin A (ManA), known as a potent inhibitor of HIF-1α, is a CMA modulator using biochemical, molecular, and cell biology approaches. We analyzed the effects of ManA on Hsp90 chaperone function by using Significant Analysis of Microarray, luciferase refolding assay, HS-10 resin binding assay, NMR spectroscopy, and SPR assay. We investigated tumor growth in response to monotherapy and combination therapy with ManA and anti-programmed death-1 (PD-1) antibody in vivo. To assess the clinical efficacy of CMA-related genes, we analyzed the gene expressions of HIF-1α, HSP90AA1, and transcription factor EB (TFEB) using TCGA datasets. Finally, we assessed in vivo/in vitro absorption, distribution, metabolism, and excretion properties of ManA.Results: ManA inhibits Hsp90 chaperone function through disruption of the Hsp90/F1F0-ATP synthase (chaperone/co-chaperone) complex. The inhibition of Hsp90 enhances the interaction of CMA substrates and LAMP-2A as well as TFEB nuclear localization, thus leading to CMA activation. Importantly, CMA activation not only retards tumor growth in vitro and in vivo, but also displays cooperative antitumor activity with anti-PD-1 antibody in vivo. An in-depth analysis of TCGA datasets shows that combined expression of HSP90AA1High/HIF1AHigh or TFEBLow/HIF1AHigh is strongly correlated with poor prognosis in lung cancer patients. Conclusions: ManA-induced inhibition of Hsp90 promotes CMA activity and decreases the stability of CMA substrates such as HIF-1α protein, leading to a marked reduction of hypoxic tumor growth. Therefore, targeting CMA activity via Hsp90 may present a promising therapeutic strategy for hypoxic tumor.

NADPH oxidase–derived reactive oxygen species (ROS) potentiate receptor tyrosine kinase (RTK) signaling, resulting in enhanced angiogenesis and tumor growth. In this study, we report that BJ-1301, a hybrid of pyridinol and alpha-tocopherol, exerts anticancer effects by dual inhibition of NADPH oxidase and RTK activities in endothelial and lung cancer cells. BJ-1301 suppresses ROS production by blocking translocation of NADPH oxidase cytosolic subunits to the cell membrane, thereby inhibiting activation. The potency of RTK inhibition by BJ-1301 was lower than that of sunitinib (a multi-RTK inhibitor), but the inhibition of downstream signaling pathways (e.g., ROS generation) and subsequent biological changes (e.g., NOX2 induction) by BJ-1301 was superior. Consistently, BJ-1301 inhibited cisplatin-resistant lung cancer cell proliferation more than sunitinib did. In xenograft chick or mouse tumor models, BJ-1301 inhibited lung tumor growth, to an extent greater than that of sunitinib or cisplatin. Treatments with BJ-1301 induced regression of tumor growth, potentially due to downregulation of autocrine-stimulatory ligands for RTKs, such as TGFα and stem cell factor, in tumor tissues. Taken together, the current study demonstrates that BJ-1301 is a promising anticancer drug for the treatment of lung cancer. Mol Cancer Ther; 16(10); 2144–56. ©2017 AACR.

5-Hydroxytryptamine (5-HT) induces proliferation of cancer cells and vascular cells. In addition to 5-HT production by several cancer cells including gastrointestinal and breast cancer, a significant level of 5-HT is released from activated platelets in the thrombotic environment of tumors, suggesting that inhibition of 5-HT signaling may constitute a new target for antiangiogenic anticancer drug discovery. In the current study we clearly demonstrate that 5-HT-induced angiogenesis was mediated through the 5-HT1 receptor-linked Gβγ/Src/PI3K pathway, but not through the MAPK/ERK/p38 pathway. In addition, 5-HT induced production of NADPH oxidase (NOX)-derived reactive oxygen species (ROS). In an effort to develop new molecularly targeted anticancer agents against 5-HT action in tumor growth, we demonstrate that BJ-1108, a derivative of 6-amino-2,4,5-trimethylpyridin-3-ol, significantly inhibited 5-HT-induced angiogenesis. In addition, BJ-1108 induced a significant reduction in the size and weight of excised tumors in breast cancer cell-inoculated CAM assay, showing proportionate suppression of tumor growth along with inhibition of angiogenesis. In human umbilical vein endothelial cells (HUVECs), BJ-1108 significantly suppressed 5-HT-induced ROS generation and phosphorylation of PI3K/Akt but not of Src. Unlike NOX inhibitors, BJ-1108, which showed better antioxidant activity than vitamin C, barely suppressed superoxide anion induced by mevalonate or geranylgeranyl pyrophosphate which directly activates NOX without help from other signaling molecules in HUVECs, implying that the anti-angiogenic action of BJ-1108 was not mediated through direct action on NOX activation, or free radical scavenging activity. In conclusion, BJ-1108 inhibited 5-HT-induced angiogenesis through PI3K/NOX signaling but not through Src, ERK, or p38.